BNP and ANP Levels Predict Whether Atrial Fibrillation Will Return After Heart Reset | Research

The takeaway

Pre-cardioversion BNP and ANP levels predicted atrial fibrillation recurrence in heart failure patients, with BNP declining after successful rhythm restoration.

Predicts recurrence
Higher pre-cardioversion natriuretic peptide levels identified patients most likely to have AF return after electrical rhythm restoration

What the researchers found

Elevated pre-cardioversion BNP and ANP predicted atrial fibrillation recurrence after DC cardioversion in mild CHF patients, and BNP declined after successful rhythm restoration.

Why it matters

Knowing which AF patients will maintain normal rhythm after cardioversion avoids futile procedures and guides treatment planning. Simple blood tests predicting success would improve clinical decision-making.

How the study worked

Prospective cohort study measuring plasma ANP and BNP before and after DC cardioversion in patients with mild congestive heart failure and atrial fibrillation. AF recurrence tracked during follow-up.

What this study cannot tell us

Small cohort of patients with mild CHF only. Specific cutoff values and predictive accuracy not detailed. Other factors also predict AF recurrence.

How to read the evidence

Moderate evidence from a prospective cohort with serial biomarker measurements and clinical follow-up.

When this study was published

Published in 2000. Natriuretic peptides are now routinely used in AF and heart failure management.

The bigger picture

Precision medicine in cardiology means treating the right patients with the right interventions. Natriuretic peptide-guided cardioversion decisions could improve outcomes and reduce unnecessary procedures.

Questions still open

Can specific BNP cutoffs identify patients likely to benefit from cardioversion?
Does pre-cardioversion peptide-guided patient selection improve outcomes?
Should natriuretic peptides be part of standard pre-cardioversion assessment?

Common questions

What is cardioversion?

It's an electrical shock that resets the heart's rhythm from atrial fibrillation (irregular beating) back to normal. The problem is AF often comes back. This study shows blood peptide levels can predict which patients will stay in normal rhythm.

How could this change treatment?

If high BNP/ANP predicts cardioversion failure, doctors might choose alternative treatments or optimize the patient's heart failure first. A simple blood test that predicts success would avoid futile procedures.

Read the original research

Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure.

Japanese circulation journal, 64(10), 765-71

View on PubMed ↗

Citation

Mabuchi, N; Tsutamoto, T; Maeda, K; Kinoshita, M. (2000). Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure.. Japanese circulation journal, 64(10), 765-71.